Parallax Volatility Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Parallax Volatility Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,000	Closed	-$3.38M	–	2385
2023 Q3	$3.38M	Buy	+30,000	New	+$3.16M	0.01%	909
2021 Q4	–	Sell	-25,500	Closed	-$2.45M	–	2169
2021 Q3	$2.45M	Buy	+25,500	New	+$2.41M	﹤0.01%	1075
2021 Q2	–	Sell	-86,200	Closed	-$8.38M	–	1545
2021 Q1	$8.38M	Buy	86,200 +85,600	+14,267%	+$8.98M	0.02%	423
2020 Q4	$58K	Sell	600 -30,100	-98%	-$2.91M	﹤0.01%	2023
2020 Q3	$2.95M	Buy	30,700 +17,900	+140%	+$2.07M	﹤0.01%	1538
2020 Q2	$1.56M	Buy	+12,800	New	+$1.41M	﹤0.01%	1560
2019 Q4	–	Sell	-50,000	Closed	-$4.51M	–	2562
2019 Q3	$4.51M	Hold	50,000	–	–	0.01%	847
2019 Q2	$4.22M	Hold	50,000	–	–	﹤0.01%	793
2019 Q1	$4.41M	Sell	50,000 -46,100	-48%	-$3.85M	0.01%	724
2018 Q4	$6.86M	Buy	96,100 +71,100	+284%	+$6.81M	0.01%	629
2018 Q3	$3.07M	Buy	+25,000	New	+$2.84M	﹤0.01%	890
2018 Q2	–	Sell	-50,000	Closed	-$4.15M	–	2881
2018 Q1	$4.15M	Buy	+50,000	New	+$4.22M	0.01%	567
2016 Q2	–	Sell	-10,000	Closed	-$396K	–	3181
2016 Q1	$396K	Buy	+10,000	New	+$397K	﹤0.01%	1531

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parallax Volatility Advisers's NBIX Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 16,173 shares — an estimated $1.72M sold.

Parallax Volatility Advisers first reported a position in NBIX in Q4 2017 and held it in 11 quarters. The position peaked at $2.01M in Q3 2021. 530 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

Parallax Volatility Advisers reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 16,173 Neurocrine Biosciences shares in Q4 2022, an estimated $1.72M.
Parallax Volatility Advisers first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 11 quarters.
Parallax Volatility Advisers's Neurocrine Biosciences position peaked at $2.01M in Q3 2021.
530 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.